10-K: Zynex Reports 2024 Results: Revenue Up, Strategic Restructuring Underway

Zynex reports a 4% increase in revenue for 2024 while implementing a restructuring plan to address temporary payment suspensions.

Summary

• Zynex, Inc. reported a 4% increase in revenue for the year ended December 31, 2024, reaching $192.4 million, compared to $184.3 million in 2023.
• Net income decreased to $3.0 million in 2024 from $9.7 million in the previous year.
• The company experienced a 16% increase in device orders.
• Operating cash flows decreased by 28% to $12.7 million.
• Zynex is implementing a restructuring plan, including a 10% staff reduction, to address a temporary payment suspension from TriCare, which represents 20-25% of annual revenue.
• The company expects the restructuring to result in approximately $35 million in annual savings.
• Zynex repurchased approximately $15.6 million worth of its common stock during the year.
• The company is developing remediation plans to address material weaknesses in internal control over financial reporting.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While revenue increased, net income and operating cash flows decreased. The company is also facing a temporary payment suspension and has identified material weaknesses in its internal controls. The restructuring plan is a positive step, but the overall outlook is uncertain.

Positives

• Device orders increased by 16% in 2024.
• Revenue increased by 4% to $192.4 million in 2024.
• The company repurchased $15.6 million of its common stock.
• The restructuring plan is expected to result in $35 million in annual savings.
• Zynex was recognized as a Best Company to Work For by U.S. News & World Report and Top Workplaces.

Negatives

• Net income decreased to $3.0 million in 2024 from $9.7 million in 2023.
• Operating cash flows decreased by 28% to $12.7 million.
• The company faces a temporary payment suspension from TriCare, representing 20-25% of annual revenue.
• Zynex identified material weaknesses in its internal controls over financial reporting.

Risks

• The temporary payment suspension from TriCare could significantly impact revenue.
• The company's ability to comply with Medicare Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Supplier Standards.
• The company's reliance on third-party payer reimbursement.
• The company's ability to maintain the reimbursement codes necessary to facilitate accurate and timely billing for our products or physician services attendant to our products.
• The company's ability to accurately estimate revenues, related refund liabilities, accounts receivable, and provider discounts.
• The company's ability to maintain insurance coverage, which could become very expensive or have limited availability.
• The company's ability to obtain regulatory clearance of new products and/or manufacturing operations we develop and maintain clearances of current products.
• The company's ability to protect the privacy, integrity and security of customer information.
• The company's ability to remediate material weaknesses in internal control over financial reporting.

Future Outlook

The company is focused on expanding its sales force and adding new complementary products to increase revenue and diversification. ZMS is focused on developing products within the non-invasive multi-parameter patient-monitoring marketplace.

Management Comments

• We are confident that long-term, our pain management business is still solid with significant growth potential.

Industry Context

The company operates in the electrotherapy and pain management market, which is estimated at approximately $500 million to $1 billion annually. The current opioid epidemic has been declared a health emergency, and Zynex is positioned to help reduce the number of opioids prescribed for treatment of chronic and acute pain symptoms.

Comparison to Industry Standards

• The company competes with International Rehabilitative Sciences, Inc. d/b/a RS Medical, EMSI, and H-Wave.
• The company also faces competition from providers of alternative medical therapies, such as pharmaceutical and medical device companies.

Legal Proceedings

• Travelers Casualty Insurance Company of America and its affiliated entities (Travelers) filed a complaint under seal in California Superior Court, County of Los Angeles against ZMI.
• Effective August 29, 2024, ZMI and Travelers entered into two settlement agreements for the collective amount of $1 million to resolve the claims asserted by Travelers in the IFPA action and for threatened claims for bills submitted to Travelers outside California.
• On December 13, 2024, the action was dismissed with prejudice and the settlement payment was made to Travelers on December 19, 2024.

Related Party Transactions

• On May 10, 2023, the disinterested Board and Audit Committee approved the purchase of 300,000 common shares of ZYXI from Mr. Sandgaard, Chairman, President, Chief Executive Officer and Principal Executive Officer, at the closing market price on May 10, 2023 of $9.61 per share for $2.9 million.
• On June 13, 2023, the disinterested Board and Audit Committee approved the purchase of 300,000 common shares of ZYXI from Mr. Sandgaard at the closing market price on June 13, 2023 of $8.62 per share for $2.6 million.

Stakeholder Impact

• Shareholders may be concerned about the decrease in net income and operating cash flows.
• Employees are affected by the 10% staff reduction.
• Customers may experience disruptions due to the temporary payment suspension from TriCare.
• Suppliers may be affected by the company's restructuring plan.

Next Steps

• The company will have a meeting with Tricare in April to discuss reinstating payments.
• The company is developing and implementing remediation plans to address the material weakness in internal control over financial reporting.

Key Dates